Blog

Deniz Can Guven: The 1st-in-human phase 1 study on arginase inhibitor INCB001158

Photo of Deniz Can Guven/X

May 18, 2024, 06:04

Deniz Can Guven: The 1st-in-human phase 1 study on arginase inhibitor INCB001158

Deniz Can Guven, Medical Oncologist at , shared on X/Twitter:

”The 1st-in-human phase 1 study on arginase inhibitor INCB001158 is out on BMJ Oncology.

Led by my great mentor Aung Naing.

Tested a strong preclinical hypothesis:

A total of 107 patients.
Monotherapy or with pembrolizumab.
+ Tolerable with fatigue and GI adverse events.
– Very limited efficacy.

Need more data on the role of arginine metabolism in TME immunosuppression. Kudos to all authors.”

Read further.
Source: Deniz Can Guven/X

Aung Naing BMJ Oncology cancer Deniz Can Guven Elena Garralda Emil Kuriakose Glenn J. Hanna Health Sciences University Howard Kallender immunotherapy Kyriakos P Papadopoulos LuLu Cheng Michael J Pishvaian Michael Smith Mike Pishvaian Omar Saavedra OncoDaily Oncology Osama Rahma pembrolizumab Sven Gogov TME immunosuppression Todd Bauer Xuejun Chen

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage